Partner Content Partner Content In-vitro Diagnostics Market profiled Qiagen, Becton Dickinso... In-vitro Diagnostics Market will reach $95bn by 2025
News ADA: AZ reveals oral GLP-1 data in obesity, diabetes AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
